Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats

被引:0
|
作者
Chu, XY [1 ]
Kato, Y [1 ]
Sugiyama, Y [1 ]
机构
[1] UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have reported previously that a canalicular multispecific organic anion transporter (cMOAT) is responsible for the biliary excretion of carboxylate forms of irinotecan, 7-ethyl-10-[4-(1-piperidino)-1 piperidino] carbonyloxy camptothecin (CPT-11), its active metabolite SN-38, and glucuronide conjugate (SN38-Glu) and the lactone form of SN38-Glu in rats. In this paper, the multiplicity of biliary excretion mechanisms for these four anionic compounds was investigated using isolated liver bile canalicular membrane vesicles (CMVs) obtained from Sprague Dawley rats. For the carboxylate form of CPT-11 and the lactone and carboxylate forms of SN38-Glu, ATP-dependent uptake consisted of both high- and low-affinity components in CMVs. Mutual inhibition studies with S-(2,4-dinitrophenyl)glutathione, a representative substrate for cMOAT, and the uptake study using CMVs from Eisai hyperbilirubinemic rats revealed that cMOAT is responsible for the biliary excretion of the low-affinity component of the carboxylate form of CPT-11 and the high-affinity component of both the lactone and carboxylate forms of SN38-Glu, whereas the high-affinity component for CPT-II and the low-affinity component for SN38-Glu, which are expressed in Eisai hyperbilirubinemic rats, are governed by a transporter different from cMOAT. The carboxylate form of SN-38 was found to be transported by cMOAT alone. We conclude that multiple transporters, including cMOAT, are responsible for the biliary excretion of CPT-II and its metabolites (anionic forms), and the contribution of each transporter differs greatly, depending on the substrates.
引用
收藏
页码:1934 / 1938
页数:5
相关论文
共 50 条
  • [41] Irinotecan Hydrochloride (CPT-11) in Dialysis Patients with Gastrointestinal Cancer
    Ashizawa, Tatsuto
    Iwahori, Tohru
    Yokoyama, Takayoshi
    Kihara, Yuu
    Konnno, Osamu
    Jyojima, Yoshimaro
    Akashi, Isao
    Nakamura, Yuuki
    Hama, Kouichirou
    Iwamoto, Hitoshi
    Segawa, Mai
    Takeuchi, Hironori
    Hirano, Toshihiko
    Nagao, Takeshi
    ACTA MEDICA OKAYAMA, 2010, 64 (01) : 19 - 26
  • [42] Intermittent, repetitive administrations of irinotecan (CPT-11) reduces its side-effects
    Fujii, H
    Koshiyama, M
    Konishi, M
    Yoshida, M
    Tauchi, K
    CANCER DETECTION AND PREVENTION, 2002, 26 (03): : 210 - 212
  • [43] Pharmacology of Topoisomerase I Inhibitors Irinotecan (CPT-11) and Topotecan
    Mathijssen, Ron H. J.
    Loos, Walter J.
    Verweij, Jaap
    Sparreboom, Alex
    CURRENT CANCER DRUG TARGETS, 2002, 2 (02) : 103 - 123
  • [44] Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11)
    Palmer, RD
    Williams, DM
    MEDICAL AND PEDIATRIC ONCOLOGY, 2003, 41 (01): : 78 - 80
  • [45] Irinotecan (CPT-11) in pretreated metastatic colorectal cancer (CRC)
    Lara, MA
    Feliu, J
    Salinas, P
    Fernandez, Y
    Garcia-Giron, C
    ANNALS OF ONCOLOGY, 1998, 9 : 45 - 46
  • [46] A Pharmacokinetic Study of Irinotecan (CPT-11) During Inflammation in Mice
    Chityala, Pavan Kumar
    Wu, Lei
    Taneja, Guncha
    Chow, Diana
    Hu, Ming
    Gao, Song
    Ghose, Romi
    FASEB JOURNAL, 2018, 32 (01):
  • [47] Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials
    Rivory, LP
    Haaz, MC
    Canal, P
    Lokiec, F
    Armand, JP
    Robert, J
    CLINICAL CANCER RESEARCH, 1997, 3 (08) : 1261 - 1266
  • [48] Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats
    Chu, XY
    Kato, Y
    Niinuma, K
    Sudo, K
    Hakusui, H
    Sugiyama, Y
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1997, 281 (01): : 304 - 314
  • [49] St. John’s Wort Modulates the Toxicities and Pharmacokinetics of CPT-11 (Irinotecan) in Rats
    Zeping Hu
    Xiaoxia Yang
    Paul Chi-Liu Ho
    Eli Chan
    Sui Yung Chan
    Congjian Xu
    Xiaotian Li
    Yi-Zhun Zhu
    Wei Duan
    Xiao Chen
    Min Huang
    Hongyuan Yang
    Shufeng Zhou
    Pharmaceutical Research, 2005, 22 : 902 - 914
  • [50] St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats
    Hu, ZP
    Yang, XX
    Ho, PCL
    Chan, E
    Chan, SY
    Xu, CJ
    Li, XT
    Zhu, YZ
    Duan, W
    Chen, X
    Huang, M
    Yang, HY
    Zhou, SF
    PHARMACEUTICAL RESEARCH, 2005, 22 (06) : 902 - 914